AR102978A1 - FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA - Google Patents
FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDAInfo
- Publication number
- AR102978A1 AR102978A1 ARP150104046A ARP150104046A AR102978A1 AR 102978 A1 AR102978 A1 AR 102978A1 AR P150104046 A ARP150104046 A AR P150104046A AR P150104046 A ARP150104046 A AR P150104046A AR 102978 A1 AR102978 A1 AR 102978A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulin glargine
- lixisenatida
- formulation
- fixed insulin
- fixed
- Prior art date
Links
- 108010057186 Insulin Glargine Proteins 0.000 title abstract 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title abstract 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002869 insulin glargine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229960001093 lixisenatide Drugs 0.000 abstract 1
- 108010004367 lixisenatide Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica que comprende (a) lixisenatida o/y una sal farmacéuticamente aceptable de la misma, y (b) insulina glargina o/y una sal farmacéuticamente aceptable de la misma, en la que el compuesto (b) y el compuesto (a) están presentes en una relación fija. Uso de la composición. Método de tratamiento de diabetes mellitus tipo 1 y/o 2.Pharmaceutical composition comprising (a) lixisenatide or / and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or / and a pharmaceutically acceptable salt thereof, wherein the compound (b) and the compound (a) They are present in a fixed relationship. Use of the composition. Method of treatment of diabetes mellitus type 1 and / or 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14197685 | 2014-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102978A1 true AR102978A1 (en) | 2017-04-05 |
Family
ID=52282387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104046A AR102978A1 (en) | 2014-12-12 | 2015-12-11 | FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR102978A1 (en) |
-
2015
- 2015-12-11 AR ARP150104046A patent/AR102978A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017006898A2 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| DOP2018000297A (en) | DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| CL2013002417A1 (en) | Compounds derived from fluoropyridinone; pharmaceutical composition comprising them; and its use in the treatment of bacterial infections. | |
| CL2013003019A1 (en) | Compounds derived from benzothiazole; pharmaceutical composition that includes them; and its use in the treatment of hiv. | |
| CL2013002053A1 (en) | Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct | |
| DOP2012000132A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN GLP-1 AND METIONINE AGONIST | |
| MX2015017540A (en) | Insulin glargine/lixisenatide fixed ratio formulation. | |
| MX389091B (en) | TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. | |
| CL2017001843A1 (en) | Lixisenatide and / or a pharmaceutically acceptable salt thereof for the treatment of pediatric patients with type 2 diabetes mellitus. | |
| ECSP16084317A (en) | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE | |
| CL2013002905A1 (en) | Pharmaceutical composition comprising fimasartan, a salt, solvate or hydrate thereof and amlodipine, an isomer, salt, solvate or hydrate thereof; Use in the treatment of hypertension and cardiovascular diseases. | |
| MX389026B (en) | A PHARMACEUTICAL COMPOSITION AND ITS USE. | |
| ES2609817T3 (en) | Leukotoxin E / D as a new anti-inflammatory agent and microbicide | |
| CL2016003023A1 (en) | "Compounds derived from (benzyl-piperazin-1-yl) (tetrahydrofuran-carbonyl or tetrahydropyran-carbonyl) substituted, rorg modulators; pharmaceutical composition comprising them; and its use in the treatment of multiple sclerosis and ankylosing spondylitis. ” pct | |
| AR102778A1 (en) | PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES | |
| CL2015000848A1 (en) | Use of a propylmethylphenol compound, or a composition comprising it, to produce a pharmaceutical and / or nutraceutical composition for the treatment and / or prophylaxis of infectious salmon anemia (isa) (divisional sol. No. 2654-12). | |
| MX2019001225A (en) | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, METHOD OF PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION OF THE SAME AND APPLICATION OF THE SAME. | |
| MX2018013729A (en) | New dapagliflozin crystal form and preparation method and use thereof. | |
| AR102978A1 (en) | FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA | |
| AR098028A1 (en) | ACID 4- [5- (3-CHLORINE-PHENOXY) -OXAZOLO [5,4-D] PYRIMIDIN-2-IL] -2,6-DIMETHYL-PHENOXYACETIC FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE RENAL INJURY | |
| ECSP18001655A (en) | Composition of multiple peptides | |
| CL2018002677A1 (en) | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. | |
| CL2013000835A1 (en) | Compounds derived from methylcyclohexane, nitric oxide modulators; pharmaceutical composition that includes them and their use in the treatment and / or prophylaxis of chronic or acute pain. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |